Literature DB >> 19349288

Measuring risk of HIV and HCV among injecting drug users in the Russian Federation.

Lucy Platt1, A J Sutton, P Vickerman, E Koshkina, S Maximova, N Latishevskaya, M Hickman, C Bonell, J Parry, T Rhodes.   

Abstract

BACKGROUND: The aim of the study was to measure risk of HIV and HCV infection among injecting drug users (IDUs) through force of infection (FOI) models in three cities of the Russian Federation and assess the value of behavioural data and FOI in predicting risk of infection as a method of second-generation surveillance.
METHODS: FOI models were fitted to prevalence data collected through an anonymous, cross-sectional community-recruited survey of IDUs with oral fluid sample collection for antibodies to HIV and HCV. Risk of infection was estimated from FOI estimates obtained by fitting a model to prevalence data by length of injecting career for each city and then overall. Risk behaviours were examined by injecting career length.
RESULTS: A total of 1473 IDUs were recruited. Prevalence of HIV was 8.1% (95% CI 6.7-9.6%) and HCV 63.4% (95% CI 60.9-65.9%). A higher FOI in new initiates to injecting (injecting career length <1 year) was found for both HIV and HCV compared with experienced IDUs (injecting career length <5 years). Increased risk of infection was not corroborated by injecting risk behaviours among new initiates into injecting (n = 38). Only 5.7% (n = 2) reported receptive sharing in the last 4 weeks, 57.9% (n = 22) sharing any injecting paraphernalia, 2.6% (n = 1) frontloading and 8.5% (n = 3) ever injecting with used needles/syringes. However, 29% of new initiates reported exchanging sex in the last 4 weeks (29%) compared with 11% long term IDUs.
CONCLUSIONS: FOI models can play an important role in surveillance of HIV but caution is needed in the interpretation of behavioural data for predicting current or future risk of HIV.

Entities:  

Mesh:

Year:  2009        PMID: 19349288     DOI: 10.1093/eurpub/ckp041

Source DB:  PubMed          Journal:  Eur J Public Health        ISSN: 1101-1262            Impact factor:   3.367


  5 in total

1.  Current and recent drug use intensifies sexual and structural HIV risk outcomes among female sex workers in the Russian Federation.

Authors:  Andrea L Wirtz; Alena Peryshkina; Vladimir Mogilniy; Chris Beyrer; Michele R Decker
Journal:  Int J Drug Policy       Date:  2015-04-25

2.  Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting.

Authors:  M Rondy; L Wiessing; S J Hutchinson; C Matheï; F Mathis; V Mravcik; L Norden; M Rosińska; O Scutelniciuc; B Suligoi; F Vallejo; M VAN Veen; M Kretzschmar
Journal:  Epidemiol Infect       Date:  2012-05-17       Impact factor: 4.434

3.  Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia.

Authors:  Anneli Uusküla; Don C Des Jarlais; Mart Kals; Kristi Rüütel; Katri Abel-Ollo; Ave Talu; Igor Sobolev
Journal:  BMC Public Health       Date:  2011-06-30       Impact factor: 3.295

4.  HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.

Authors:  Jorge Valencia La Rosa; Pablo Ryan; Alejandro Alvaro-Meca; Jesús Troya; Guillermo Cuevas; Jorge Gutiérrez; Santiago Moreno
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

5.  A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs.

Authors:  Vivian D Hope; Ross J Harris; Peter Vickerman; Lucy Platt; Justin Shute; Katelyn J Cullen; Samreen Ijaz; Sema Mandal; Fortune Ncube; Monica Desai; John V Parry
Journal:  Euro Surveill       Date:  2018-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.